Study of Liraglutide (A Weight Loss Drug) in High Risk Obese Participants With Cognitive and Memory Issues

NCT06171152 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

SUSPENDED

Status

30

Enrollment

OTHER

Sponsor class

Stopped Study pending amendment

Conditions

Multiple Sclerosis
Long COVID
Long Covid19
Obese
Obesity
Obesity, Morbid
Acute Leukemia in Remission

Interventions

DRUG: Liraglutide Pen Injector [Saxenda]
OTHER: Medication Diary

Sponsor

University of Chicago